-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Vanda Pharmaceuticals Inc. Just Missed EPS By 58%: Here's What Analysts Think Will Happen Next
Vanda Pharmaceuticals Inc. Just Missed EPS By 58%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), which a week ago released some disappointing second-quarter results that could have a notable impact on how the market views the stock. Results showed a clear earnings miss, with US$64m revenue coming in 3.9% lower than what the analystexpected. Statutory earnings per share (EPS) of US$0.05 missed the mark badly, arriving some 58% below what was expected. Following the result, the analyst has updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analyst latest (statutory) post-earnings forecasts for next year.
See our latest analysis for Vanda Pharmaceuticals
NasdaqGM:VNDA Earnings and Revenue Growth August 6th 2022Following last week's earnings report, Vanda Pharmaceuticals' sole analyst are forecasting 2022 revenues to be US$264.9m, approximately in line with the last 12 months. Statutory earnings per share are forecast to dip 7.5% to US$0.18 in the same period. Before this earnings report, the analyst had been forecasting revenues of US$267.3m and earnings per share (EPS) of US$0.30 in 2022. The analyst seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a pretty serious reduction to EPS estimates.
It might be a surprise to learn that the consensus price target fell 55% to US$10.00, with the analyst clearly linking lower forecast earnings to the performance of the stock price.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Vanda Pharmaceuticals' revenue growth is expected to slow, with the forecast 1.7% annualised growth rate until the end of 2022 being well below the historical 11% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 14% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Vanda Pharmaceuticals.
The Bottom Line
The most important thing to take away is that the analyst downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply revenues will perform worse than the wider industry. Furthermore, the analyst also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
With that in mind, we wouldn't be too quick to come to a conclusion on Vanda Pharmaceuticals. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2024, which can be seen for free on our platform here.
However, before you get too enthused, we've discovered 2 warning signs for Vanda Pharmaceuticals that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
這將是一段艱難的時期萬達製藥公司。納斯達克(Sequoia Capital:VNDA)一週前發佈了一些令人失望的第二季度業績,可能會對市場如何看待該股產生顯著影響。結果顯示,盈利低於預期,6400萬美元的收入比分析師預期的低3.9%。法定每股收益(EPS)為0.05美元,嚴重低於預期,比預期低約58%。結果公佈後,這位分析師更新了他們的收益模型,如果他們認為公司的前景發生了巨大變化,還是一切照舊,那將是一件好事。我們認為,讀者會發現,分析師對明年最新的(法定)盈利預測會很有趣。
查看我們對萬達製藥的最新分析
NasdaqGM:VNDA收益和收入增長2022年8月6日在上週的收益報告之後,Vanda PharmPharmticals的唯一分析師預測2022年收入將達到2.649億美元,與過去12個月大致一致。預計同期法定每股收益將下降7.5%,至0.18美元。在這份收益報告之前,分析師一直預測2022年收入為2.673億美元,每股收益(EPS)為0.30美元。在最新結果公佈後,這位分析師似乎變得更加悲觀。雖然營收預期沒有變化,但每股收益預期出現了相當嚴重的下調。
可能會令人驚訝的是,共識目標價下跌55%,至10.00美元,分析師明確將較低的預期收益與股價表現聯繫在一起。
瞭解這些預測的更多背景信息的一種方法是,看看它們與過去的表現如何比較,以及同行業的其他公司的表現如何。我們要強調的是,萬達製藥的收入增長預計將放緩,截至2022年底的預測年化增長率為1.7%,遠低於歷史上每年11%的增長率。過去五年的增長。相比之下,分析師覆蓋的該行業其他公司的收入預計將以每年14%的速度增長。因此,很明顯,雖然收入增長預計將放緩,但整個行業的增長速度預計也將快於萬達製藥。
底線
最重要的是,這位分析師下調了他們的每股收益預期,表明在這些結果公佈後,市場情緒明顯下降。從積極的一面來看,營收預期沒有重大變化;儘管預測意味着營收表現將遜於整個行業。此外,分析師還下調了他們的目標價,這表明最新消息導致人們對該業務的內在價值更加悲觀。
考慮到這一點,我們不會太快得出關於萬達製藥的結論。長期盈利能力比明年的利潤重要得多。至少有一位分析師提供了對2024年的預測,這可以在我們的平臺上免費看到。
然而,在你太興奮之前,我們已經發現萬達製藥的2個警告信號這一點你應該知道。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧